News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sanofi (France) (SASY.PA) to Lay Off Hundreds in Sales and R&D



11/2/2011 8:07:12 AM

In the aftermath of the Genzyme acquisition, Sanofi told employees this morning about plans to shift various R&D operations between New Jersey and Massachusetts, as well as scaling back the sales force, primarily in the cardiovascular and oncology groups. All told, hundreds of jobs will be eliminated, although a spokesman was unable to specify the actual number until more details are sorted out. The cutbacks are hardly suprising, though. A few weeks ago, Sanofi disclosed plans to cut another $2.9 billion in costs in hopes of coping with upcoming expiration of patents on big-selling meds, notably the Plavix bloodthinner and Avapro high blood pressure medicine. R&D costs, for instance, are in the process of being cut by 12 percent from 2008 to about $1.1 billion, excluding Genzyme. And the overall headcount is being reduced from 13,000 to 10,000 (back story).

Read at Pharmalot
Read at Reuters
Read at Business Week
Read at NPR News
Read at AP


comments powered by Disqus
Pharmalot
Reuters
Business Week
NPR News
AP
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES